Chandan Healthcare Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Chandan Healthcare Limited's achieved publicly listed status following its IPO debut on Feb 17, 2025 at the NSE platform. The offering successfully mobilized 67,52,000 Shares, with 44,52,064 Shares allocated to corporate growth initiatives and ₹36.57 Cr providing liquidity to existing shareholders.
Investment participation occurred within the established price band of ₹151 to ₹159, starting from minimum lots of 800 shares. The subscription window from Feb 10, 2025 through Feb 12, 2025 enabled investor participation across market segments.
Share allocation was completed on Feb 13, 2025, determining ownership distribution among successful applicants. The listing represents a milestone achievement, transitioning the company to regulated public market status with associated responsibilities and opportunities.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Established in September 2003, Chandan Healthcare Limited is a leading diagnostic network in North India, offering a wide range of pathology and radiology services. The company operates a flagship lab, seven central labs, 26 satellite centres, and over 300 collection centres across 23 cities in Uttar Pradesh and more than 19 in Uttarakhand. Its portfolio includes 1,496 tests covering routine pathology, specialized diagnostics, and advanced imaging such as X-rays, CT scans, MRIs, and ultrasounds. Supported by a team of radiologists, pathologists, and skilled professionals, Chandan Healthcare is dedicated to providing accurate, reliable, and accessible diagnostic services across its growing network.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Wide Regional Reach – Well-connected across North India, covering 39 tier-two cities and towns in Uttarakhand for easy accessibility.
- All-in-One Diagnostic Services – Offering a full range of pathology, radiology tests, and medical consultations with 1,496 test options.
- Strong & Stable Growth – Consistently profitable with a solid financial foundation, ensuring long-term reliability.
- Dependence on Key Centers – If major diagnostic centers face disruptions, it could affect test processing, business operations, and financial performance.
- Brand Importance – The company's success relies on maintaining a strong brand reputation, which could be challenged by competition or service issues.
- Revenue Risks – A large share of earnings comes from B2C and a few key clients, but without long-term contracts, revenue could fluctuate if agreements aren’t renewed.
- Amaranita Holdings (India) Private Limited
- Amar Singh
- Asmita Singh
- Alok Singh
- Shaleen Solanki
- Vijay Singh
- Vinay Lamba
Chandan Healthcare Limited
Kfin Technologies Limited